Physician profile
Jack D Anderson
NPI 1245527969
$1,424.89
in general payments reported to CMS, 2019-2025
25 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $98.97 · 2022: $268 · 2023: $279 · 2024: $273 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $950.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $334.37 | 2022-2025 | Vraylar |
| Lilly USA, LLC | $208.80 | 2020-2025 | Mounjaro |
| Pfizer INC. | $115.91 | 2022-2025 | |
| Glaxosmithkline, LLC. | $86.67 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $69.34 | 2023-2025 | Trintellix |
| Novo Nordisk INC | $66.45 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $57.99 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.47 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $52.38 | 2023-2024 | Evusheld, Breztri, Farxiga |
| Indivior INC. | $48.06 | 2024-2025 | Sublocade |
| Exact Sciences Corporation | $46.27 | 2024-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $36.17 | 2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $33.46 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $28.78 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $28.35 | 2024-2025 | Voquezna |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $21.43 | 2022 | |
| Allergan, INC. | $18.36 | 2019 | |
| Avanir Pharmaceuticals, INC. | $16.38 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.93 | 2025 | Zoryve |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.49 | 2024 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.84 | 2025 | Xifaxan |
| Shield Therapeutics INC | $13.90 | 2022 | |
| Amgen INC. | $13.37 | 2023 | Otezla, Repatha |
| Genentech USA, INC. | $13.07 | 2020 | |
| Ironwood Pharmaceuticals, INC | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.